NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Workspace · Cancer algorithms · Small intestine

Small intestine

Small intestine · 14,450 new · 2,170 deaths (ACS 2026) · mortality 0.5 per 100k · 5-yr RS 71.8% (SEER)

Mortality 0.5 per 100k (SEER / ACS common-sites). Never an artboard percent.

Lifetime ≈ 0.3% (SEER Stat Facts). 93,952 people living with small intestine cancer in 2023. No encoded screening interval.

93,952 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 66 · at death 73 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 3.1 / women 2.4 per 100k · mortality men 0.5 / women 0.4 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 65–74. Deaths highest among people aged 75–84. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases rising 2.3% each year (2014–2023). Death rates rising 1.8% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.

Highest new-case rate: Non-Hispanic Black men 4.9 per 100k. Highest death rate: Non-Hispanic Black men 0.9 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
Group	Inc. men	Inc. women	Deaths men	Deaths women
Hispanic	2.3	2.1	0.4	0.3
Non-Hispanic American Indian/Alaska Native	2.4	2.1	0.7	—
Non-Hispanic Asian/Pacific Islander	1.9	1.3	0.3	0.2
Non-Hispanic Black	4.9	4.1	0.9	0.6
Non-Hispanic White	3.2	2.4	0.5	0.4

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

No USPSTF population-screening recommendation is cited for this stub.

ACS / SEER pin only. Not encoded. Not a screening recommendation.

ACS early-detection pointer

ACS 2026 · People at average risk of small-intestine cancer · ACS (2026): routine testing for people at average risk is not recommended. Inherited-syndrome follow-up is named but not encoded. Not an enteroscopy engine.

Cited ACS statement only. Not a screening engine. ACS-intestine-detect

Surveillance pointer

ACS-intestine-follow 2026 · cited only · ACS after-treatment page names follow-up visits that may include symptoms, exam, blood tests, or CT, typically every few months at first. Those months are not encoded. Not an enteroscopy engine.

Named public source only. Not a personal follow-up calendar. ACS-intestine-follow

Surveillance pointer

ACS-intestine-follow 2026 · cited only · ACS after-treatment page names later cancers after small-intestine treatment, especially other digestive-tract cancers including colorectal. Named later-cancer sites are not encoded. Complementary to the living-as pointer. Not an enteroscopy or second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-intestine-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names bowel blockage from adhesions after abdomen or pelvis treatment, plus urinary retention, leakage, or UTIs, and fertility effects after chemo or radiation to the pelvis, belly, or spine. Those names are not encoded. Complementary to the living-as pointer. Not an enteroscopy engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Those plans are not encoded. Complementary to the GI printout. Not an enteroscopy engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Toxicity pointer

ACS-intestine-follow 2026 · empty on purpose · ACS after-treatment page names treatment side effects. Those late effects are not encoded. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-intestine-follow

Toxicity pointer

ACS-intestine-follow 2026 · empty on purpose · ACS after-treatment page names later cancers after small-intestine treatment. Those second-cancer risks are not encoded. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-intestine-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later bowel blockage from adhesions, urinary retention, and fertility effects after abdomen or pelvis treatment. Those late effects are not encoded. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after abdomen or pelvis treatment. Those named tests are not encoded. Complementary to the GI printout. Not an enteroscopy engine. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Late toxicity printout

Late toxicity printout — GI

Acute: ACS names nausea, heartburn, cramps, diarrhea or constipation, bowel urgency, and rectal or anal skin irritation. Late: radiation proctitis, bowel incontinence, ostomy or chronic bowel change, neuropathy, adhesions, urinary trouble after pelvis RT, fertility effects, sexuality changes, lasting fatigue, cavities after chemo, and cognitive change after chemo. Monitor: on-treatment diarrhea; proctitis after 3 to 6 months; lasting fatigue or sleep problems; sexuality or body-image change; fertility after pelvis, belly, or spine treatment; cavity risk after chemo; memory, thinking, or focus change after chemo; a treatment summary and second-cancer watching. Those names are not encoded. Official esophagus share-of-new-cases figures are not restated. Not a Lynch or endoscopy engine.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

Bowel obstruction from adhesions
Urinary retention or incontinence after pelvis RT
Fertility after pelvis, belly, or spine RT
Sexuality after cancer treatment
Cancer-related fatigue that lasts
Joint or muscle pain after some treatments
Mental health and distress after treatment
Cavities and tooth loss after chemo
Cognitive impairment after brain RT or chemo

Named conditions to monitor

Diarrhea that starts during abdomen RT
Radiation proctitis after 3 to 6 months
Second-cancer testing
Bowel blockage or bladder-emptying trouble
Cancer-related fatigue or sleep problems that last
Joint or muscle pain after chemo, steroids, or hormone therapy
Anxiety, depression, or fear of recurrence after treatment
Sexuality or body-image change after treatment
Fertility after pelvis, belly, or spine treatment
Cavity risk after chemo
New or worsening memory, thinking, or focus
Second-cancer awareness after radiation or chemo
Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS abdomen / pelvis / CRC names only. Complementary ACS long-term page is named, not encoded. Official esophagus share-of-new-cases figures are not restated. No invented trial percent.

Open GI printout →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-intestine · stub · none · v2-stub-intestine

SEER 5-year relative survival by stage (cited stub)

Localized 86.3% · Regional 79.6% · Distant 47.9% · All 71.8%

Small intestine. SEER Cancer Stat Facts.

Percent of cases by stage (SEER Stat Facts)

Localized 33% · Regional 33% · Distant 27% · Unknown 7%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Small intestine.

lifetime
Small intestine birth-to-death
≈ 0.3%

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — routine average-risk small-intestine testing not recommended
Cited ACS 2026 statement only. Not an enteroscopy engine.
not encoded
surveillance
ACS follow-up cited — intestine months not encoded
Cited ACS after-treatment page only. Not an enteroscopy engine.
not encoded
toxicity
ACS late effects cited — intestine months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — routine average-risk small-intestine testing not recommended
Cited ACS 2026 statement only. Not an enteroscopy engine.
not encoded
surveillance
ACS follow-up cited — intestine months not encoded
Cited ACS after-treatment page only. Not an enteroscopy engine.
not encoded
toxicity
ACS late effects cited — intestine months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — routine average-risk small-intestine testing not recommended
Cited ACS 2026 statement only. Not an enteroscopy engine.
not encoded
surveillance
ACS follow-up cited — intestine months not encoded
Cited ACS after-treatment page only. Not an enteroscopy engine.
not encoded
toxicity
ACS late effects cited — intestine months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — routine average-risk small-intestine testing not recommended
Cited ACS 2026 statement only. Not an enteroscopy engine.
not encoded
surveillance
ACS follow-up cited — intestine months not encoded
Cited ACS after-treatment page only. Not an enteroscopy engine.
not encoded
toxicity
ACS late effects cited — intestine months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →